Marker Therapeutics Inc (MRKR)

[microcapbiotech]

From Oppenheimer:
"responses to MultiTAA therapy have been achieved without lymphodepletive preconditioning and cytokine support and at considerably lower doses vs. other adoptive T cell therapies. If results from the early BCM studies can be validated in a larger, multi-center trial, we believe MultiTAA could provide a distinct safety advantage over the current generation of CAR-T and TIL products."

YEP

"While our valuation rests on the potential of MultiTAA in AML, we acknowledge the broader potential of MultiTAA in other cancers. Later this month, we expect BCM to present first-in-human data from an ongoing trial in pancreatic cancer, MultiTAA’s first solid tumor indication. Given low investor expectations for cell therapies in this indication, we see little downside risk heading into the readout."

YEP

First line: "While our valuation rests on the potential of MultiTAA in AML, we acknowledge the broader potential of MultiTAA in other cancers."

is that an understatement or what?